IL307726A - Multimeric oligonucleotides with reduced renal clearance - Google Patents
Multimeric oligonucleotides with reduced renal clearanceInfo
- Publication number
- IL307726A IL307726A IL307726A IL30772623A IL307726A IL 307726 A IL307726 A IL 307726A IL 307726 A IL307726 A IL 307726A IL 30772623 A IL30772623 A IL 30772623A IL 307726 A IL307726 A IL 307726A
- Authority
- IL
- Israel
- Prior art keywords
- kidney clearance
- decreased kidney
- multimeric oligonucleotides
- multimeric
- oligonucleotides
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 230000003247 decreasing effect Effects 0.000 title 1
- 210000003734 kidney Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455231P | 2017-02-06 | 2017-02-06 | |
| US201762522363P | 2017-06-20 | 2017-06-20 | |
| US201762561853P | 2017-09-22 | 2017-09-22 | |
| PCT/US2018/017062 WO2018145086A1 (en) | 2017-02-06 | 2018-02-06 | Multimeric oligonucleotides having decreased kidney clearance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL307726A true IL307726A (en) | 2023-12-01 |
Family
ID=63039118
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307726A IL307726A (en) | 2017-02-06 | 2018-02-06 | Multimeric oligonucleotides with reduced renal clearance |
| IL267806A IL267806B2 (en) | 2017-02-06 | 2018-02-06 | Multimeric oligonucleotides having decreased kidney clearance |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL267806A IL267806B2 (en) | 2017-02-06 | 2018-02-06 | Multimeric oligonucleotides having decreased kidney clearance |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11078484B2 (enExample) |
| EP (1) | EP3576752A4 (enExample) |
| JP (1) | JP7183167B2 (enExample) |
| KR (2) | KR102623311B1 (enExample) |
| CN (1) | CN110248665A (enExample) |
| AU (1) | AU2018215684B2 (enExample) |
| CA (1) | CA3051480A1 (enExample) |
| IL (2) | IL307726A (enExample) |
| MX (1) | MX2019009347A (enExample) |
| SG (1) | SG11201906728TA (enExample) |
| WO (1) | WO2018145086A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101141544B1 (ko) | 2009-03-13 | 2012-05-03 | 한국과학기술원 | 에스아이알엔에이 다중 접합체 및 이의 제조방법 |
| IL316159A (en) * | 2015-06-15 | 2024-12-01 | Mpeg La Llc | Defined Oligonucleotide Multimers and Methods for Manufacture Thereof |
| CN110248665A (zh) | 2017-02-06 | 2019-09-17 | Mpeg La有限责任公司 | 具有降低的肾清除的多聚体寡核苷酸 |
| US20230287406A1 (en) * | 2019-03-04 | 2023-09-14 | Mpeg La, L.L.C. | Multimeric oligonucleotides with enhanced bioactivity |
| AU2020252020A1 (en) * | 2019-03-29 | 2021-11-11 | University Of Massachusetts | Oligonucleotide-based modulation of C90RF72 |
| EP3966328A4 (en) | 2019-05-06 | 2023-10-18 | University Of Massachusetts | Anti-c9orf72 oligonucleotides and related methods |
| US20230114023A1 (en) * | 2019-07-30 | 2023-04-13 | Mpeg La, L.L.C. | Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity |
| WO2021026476A1 (en) * | 2019-08-08 | 2021-02-11 | Mpeg La, L.L.C. | Complement targeting with multimeric oligonucleotides |
| WO2021222635A2 (en) * | 2020-04-30 | 2021-11-04 | Mpeg La, L.L.C. | Multimeric oligonucleotides with divided strands |
| EP4149557A4 (en) * | 2020-05-13 | 2025-01-15 | The University of North Carolina at Chapel Hill | Nucleic acid ligand conjugates and use thereof for delivery to cells |
| WO2021236689A1 (en) * | 2020-05-19 | 2021-11-25 | Mpeg La, L.L.C. | Orthogonally linked multimeric oligonucleotides |
| AU2024265748A1 (en) | 2023-05-04 | 2025-10-23 | Argonaute RNA Limited | Dual silencing |
| GB2702002A (en) | 2024-10-25 | 2026-05-27 | Argonaute Rna Ltd | Gene silencing of cardiovascular genes |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9207381D0 (en) * | 1992-04-03 | 1992-05-13 | Ici Plc | Synthesis of oligonucleotides |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| WO2004030634A2 (en) | 2002-10-02 | 2004-04-15 | Alnylam Pharmaceuticals Inc. | Therapeutic compositions |
| CA2518475C (en) | 2003-03-07 | 2014-12-23 | Alnylam Pharmaceuticals, Inc. | Irna agents comprising asymmetrical modifications |
| JP2006522158A (ja) | 2003-04-03 | 2006-09-28 | アルナイラム ファーマシューティカルズ インコーポレイテッド | ｉＲＮＡ複合体 |
| US8969543B2 (en) | 2003-04-03 | 2015-03-03 | Bioneer Corporation | SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof |
| WO2004091515A2 (en) | 2003-04-09 | 2004-10-28 | Alnylam Pharmaceuticals, Inc. | iRNA CONJUGATES |
| AU2004230927B9 (en) | 2003-04-13 | 2011-12-01 | Enzon Pharmaceuticals, Inc. | Polymeric oligonucleotide prodrugs |
| EP2669377A3 (en) | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
| CA2522349A1 (en) | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals, Inc. | Protected monomers |
| US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| EP1807520B1 (en) | 2004-10-25 | 2012-07-25 | Devgen NV | Rna constructs |
| US20100003753A1 (en) | 2005-08-01 | 2010-01-07 | Purdue Research Foundation | Multivalent rna nanoparticles for delivery of active agents to a cell |
| CA2648585C (en) | 2006-04-07 | 2017-07-25 | Idera Pharmaceuticals, Inc. | Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8 |
| US8748405B2 (en) | 2007-01-26 | 2014-06-10 | City Of Hope | Methods and compositions for the treatment of cancer or other diseases |
| US20080214436A1 (en) | 2007-01-26 | 2008-09-04 | City Of Hope | Methods and compositions for the treatment of cancer or other diseases |
| WO2008109373A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting erbb gene expression and uses thereof |
| WO2008109105A2 (en) | 2007-03-06 | 2008-09-12 | Flagship Ventures | Methods and compositions for improved therapeutic effects with sirna |
| KR101343489B1 (ko) | 2007-07-09 | 2013-12-20 | 이데라 파마슈티칼즈, 인코포레이티드 | 안정화된 면역 조절성 ｒｎａ（ｓｉｍｒａ）화합물 |
| US8575123B2 (en) | 2008-04-11 | 2013-11-05 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| US9433684B2 (en) | 2008-08-19 | 2016-09-06 | Nektar Therapeutics | Conjugates of small-interfering nucleic acids |
| US8637194B2 (en) | 2008-09-02 | 2014-01-28 | Bio-Nano Power, Llc | Bio-nano power cells and their uses |
| BRPI0923225A2 (pt) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | metodo para sintese de acidos nucleicos modificados no atomo de fosforo |
| WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| WO2010090452A2 (ko) * | 2009-02-04 | 2010-08-12 | 성균관대학교산학협력단 | 세포 내 전달능이 증가된 작은 간섭 rna 복합체 |
| KR101141544B1 (ko) | 2009-03-13 | 2012-05-03 | 한국과학기술원 | 에스아이알엔에이 다중 접합체 및 이의 제조방법 |
| HUE026020T2 (en) | 2009-08-27 | 2016-05-30 | Idera Pharmaceuticals Inc | Preparation for inhibiting gene expression and its uses |
| KR101678876B1 (ko) | 2010-01-15 | 2016-11-23 | 한국과학기술원 | 복합 유전자를 표적하는 ｓｉＲＮＡ 다중 접합체 및 이의 제조방법 |
| PH12012501596A1 (en) | 2010-02-24 | 2017-02-03 | Arrowhead Res Corporation | Compositions for targeted delivery of sirna |
| WO2011109380A1 (en) * | 2010-03-01 | 2011-09-09 | The Children's Hospital Of Philadelphia | Nucleic acids for targeting multiple regions of the hcv genome |
| CN107365339A (zh) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| KR101340290B1 (ko) * | 2011-09-14 | 2013-12-11 | 한국과학기술원 | 유전자 표적용 ｓｉＲＮＡ 하이드로젤 및 그 제조방법 |
| HK1200484A1 (zh) | 2011-09-14 | 2015-08-07 | Translate Bio Ma, Inc. | 多聚寡核苷酸化合物 |
| US20150247141A1 (en) | 2012-09-14 | 2015-09-03 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
| WO2014113802A1 (en) | 2013-01-18 | 2014-07-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | TARGETED SENSITIZATION OF NON-DEL(5q) MALIGNANT CELLS |
| KR101629681B1 (ko) | 2013-06-24 | 2016-06-14 | 건국대학교 산학협력단 | 다중 리간드가 도입된 에스아이알엔에이 접합체 |
| GB201311840D0 (en) * | 2013-07-02 | 2013-08-14 | Univ Aberdeen | Control of varroa mite infestation |
| EP2845607A1 (en) | 2013-09-09 | 2015-03-11 | University of Vienna | Antisense oligonucleotides with improved pharmacokinetic properties |
| WO2015089368A2 (en) | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
| US10358643B2 (en) | 2014-01-30 | 2019-07-23 | Hoffmann-La Roche, Inc. | Poly oligomer compound with biocleavable conjugates |
| WO2016110691A1 (en) * | 2015-01-06 | 2016-07-14 | The University Court Of The University Of Aberdeen | Enhanced rnai mediated gene regulation |
| IL316159A (en) | 2015-06-15 | 2024-12-01 | Mpeg La Llc | Defined Oligonucleotide Multimers and Methods for Manufacture Thereof |
| WO2017004357A1 (en) | 2015-07-02 | 2017-01-05 | City Of Hope | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof |
| WO2017075030A1 (en) | 2015-10-26 | 2017-05-04 | Rana Therapeutics, Inc. | Methods and compositions for increasing smn expression |
| CA3010593C (en) | 2016-01-05 | 2024-02-13 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| JP7016317B2 (ja) | 2016-08-08 | 2022-02-21 | 浩文 山本 | アジュバント組成物 |
| CN110248665A (zh) | 2017-02-06 | 2019-09-17 | Mpeg La有限责任公司 | 具有降低的肾清除的多聚体寡核苷酸 |
| CN111164091B (zh) | 2017-06-02 | 2025-01-07 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| EP3733683A4 (en) | 2017-11-30 | 2022-04-06 | GeneMind Biosciences Company Limited | NUCLEOSIDE ANALOGUES, METHOD OF MANUFACTURE AND USE |
| US20230287406A1 (en) | 2019-03-04 | 2023-09-14 | Mpeg La, L.L.C. | Multimeric oligonucleotides with enhanced bioactivity |
| US20230114023A1 (en) | 2019-07-30 | 2023-04-13 | Mpeg La, L.L.C. | Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity |
| WO2021236689A1 (en) | 2020-05-19 | 2021-11-25 | Mpeg La, L.L.C. | Orthogonally linked multimeric oligonucleotides |
-
2018
- 2018-02-06 CN CN201880010283.4A patent/CN110248665A/zh active Pending
- 2018-02-06 SG SG11201906728TA patent/SG11201906728TA/en unknown
- 2018-02-06 MX MX2019009347A patent/MX2019009347A/es unknown
- 2018-02-06 AU AU2018215684A patent/AU2018215684B2/en active Active
- 2018-02-06 KR KR1020197023090A patent/KR102623311B1/ko active Active
- 2018-02-06 IL IL307726A patent/IL307726A/en unknown
- 2018-02-06 WO PCT/US2018/017062 patent/WO2018145086A1/en not_active Ceased
- 2018-02-06 JP JP2019542485A patent/JP7183167B2/ja active Active
- 2018-02-06 EP EP18747398.8A patent/EP3576752A4/en active Pending
- 2018-02-06 CA CA3051480A patent/CA3051480A1/en active Pending
- 2018-02-06 IL IL267806A patent/IL267806B2/en unknown
- 2018-02-06 KR KR1020247000303A patent/KR102776167B1/ko active Active
- 2018-02-06 US US15/889,975 patent/US11078484B2/en active Active
-
2021
- 2021-07-01 US US17/305,225 patent/US12378551B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3576752A4 (en) | 2020-12-16 |
| MX2019009347A (es) | 2019-10-07 |
| IL267806B1 (en) | 2023-11-01 |
| IL267806A (en) | 2019-09-26 |
| SG11201906728TA (en) | 2019-08-27 |
| KR20240010750A (ko) | 2024-01-24 |
| CA3051480A1 (en) | 2018-08-09 |
| WO2018145086A1 (en) | 2018-08-09 |
| IL267806B2 (en) | 2024-03-01 |
| JP7183167B2 (ja) | 2022-12-05 |
| US12378551B2 (en) | 2025-08-05 |
| AU2018215684B2 (en) | 2024-03-07 |
| US20180223284A1 (en) | 2018-08-09 |
| KR102623311B1 (ko) | 2024-01-10 |
| US11078484B2 (en) | 2021-08-03 |
| JP2020518552A (ja) | 2020-06-25 |
| KR20190115445A (ko) | 2019-10-11 |
| EP3576752A1 (en) | 2019-12-11 |
| US20210380979A1 (en) | 2021-12-09 |
| AU2018215684A1 (en) | 2019-08-01 |
| CN110248665A (zh) | 2019-09-17 |
| KR102776167B1 (ko) | 2025-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267806A (en) | Multimeric oligonucleotides with reduced renal clearance | |
| IL266100A (en) | Multimeric il-15 based molecules | |
| IL256169A (en) | Multi-conjugated oligonucleotides are defined | |
| IL290070A (en) | pump | |
| GB2554254B (en) | Pump | |
| AU364468S (en) | Pump | |
| GB201503408D0 (en) | Oligonucleotides | |
| AU366816S (en) | Pump | |
| GB201504124D0 (en) | Oligonucleotides | |
| GB2554293B (en) | Pump | |
| GB201517241D0 (en) | DNA modification | |
| GB201518622D0 (en) | Pump | |
| GB2543832B (en) | Pump driver | |
| GB201714330D0 (en) | Oligonucleotides | |
| HK40015387A (en) | Multimeric oligonucleotides having decreased kidney clearance | |
| GB201506773D0 (en) | Pump | |
| GB201713546D0 (en) | DNA assembly | |
| GB201718608D0 (en) | Improved pump | |
| GB201707049D0 (en) | DNA Assembly | |
| GB201608069D0 (en) | Cavitation reduction | |
| GB201507865D0 (en) | Cavitation reduction | |
| PT3332121T (pt) | Bomba | |
| AU201612351S (en) | Pump | |
| GB201520883D0 (en) | Single molecule controls | |
| GB201502442D0 (en) | NTT passport |